CPDA-1 19.3 mg/70mL (Anticoagulant Citrate Phosphate Dextrose Adenine SOLUTION) 19.3 mg/70mL

CPDA-1 19.3 mg/70mL is an anticoagulant solution used to preserve blood components. This intravenous solution contains citrate, phosphate, dextrose, and adenine, designed for blood storage and transfusion purposes.

Strength

19.3 mg/70mL

Pack Size

70 mL in 1 BAG (0942-6307-02)

Manufacturer / TM Owner

Fenwal, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

CPDA-1 19.3 mg/70mL is primarily used to prevent blood clotting during storage. This anticoagulant solution is commonly employed in medical settings to extend the shelf life of blood components, ensuring they remain viable for transfusion. The solution's formulation helps maintain the integrity of red blood cells and other blood components, making it essential for blood banks and hospitals.

Side Effects

When used as directed, CPDA-1 19.3 mg/70mL helps to preserve blood components by preventing coagulation. The solution's ingredients work together to maintain the quality of blood, ensuring it remains suitable for transfusion. Users may notice that the blood components retain their properties for a longer period when stored in this solution.

Precautions & Warnings

CPDA-1 19.3 mg/70mL should be handled with care to avoid contamination. It is important to follow proper storage guidelines and use sterile techniques when preparing and administering the solution. Always check the solution for any signs of contamination or discoloration before use.

Avoid Interactions

CPDA-1 19.3 mg/70mL is generally used in controlled medical environments, so interactions with other medications are typically monitored by healthcare professionals. However, it is important to inform your healthcare provider about any other medications you are taking to avoid potential complications.

Frequently Asked Questions

CPDA-1 19.3 mg/70mL is used to preserve blood components by preventing clotting during storage.

CPDA-1 19.3 mg/70mL should be stored according to the manufacturer's guidelines to maintain its efficacy.

The main ingredients in CPDA-1 19.3 mg/70mL include citrate, phosphate, dextrose, and adenine.

Interactions with other medications should be discussed with a healthcare professional.

The shelf life of blood stored in CPDA-1 19.3 mg/70mL varies and should be determined by medical guidelines.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.